Where are the headquarters of the company that developed Crizanlizumab?
Crizanlizumab: Crizanlizumab is a monoclonal antibody developed by Novartis targeted towards P-selectin. Novartis: Novartis International AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland.
Basel, Switzerland